Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XAB05 Phase 1 in Healthy Volunteers
NCT05307406Phase 1Completed
- Sponsor
- Xenothera
- Start
- Jan 2022
- Primary completion
- May 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in bacterial infection comparing XAB05 with Placebo (2 arms). Primary endpoints: Safety and tolerability parameters: physical examination, Safety and tolerability parameters: Adverse events (AEs) and 7 more. Started Jan 2022; status: completed.
02
Drugs
XAB05
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT05307406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05307406.